Cytek Biosciences, Inc. (DE:8EQ)
NASDAQ:8EQ
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.03Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a mix of constructive commercial momentum—led by a strong U.S. rebound, double-digit growth in recurring revenue, robust installed base expansion and growing cloud/user engagement—while also disclosing near-term profitability pressures from higher operating and legal expenses, regional disruption (EMEA) and APAC order timing. Management reaffirmed full-year guidance and expects adjusted EBITDA to turn positive for 2026, supported by a strong balance sheet.Company Guidance
Revenue Growth and Constructive Start to 2026
Q1 2026 revenue was $44.1M, up 6% year-over-year from $41.5M, representing a constructive start to the year and management's view of a return to more normal U.S. market conditions.
Strong U.S. Performance
U.S. revenue was $24.4M, up 32% year-over-year (from $18.5M), driven by broad-based instrument sales to academic institutions and biopharma customers and repeat buyers.
Recurring Revenue Momentum
Trailing 12-month combined reagents and service revenue reached $18.4M, representing 35% of total revenue and growing 19% year-over-year, indicating increasing recurring revenue contribution.
Services and Reagents Double-Digit Growth
Service revenue grew 15% year-over-year to $15.4M; reagent revenue grew mid-teens (management cited a 16% growth figure), with particularly strong reagent growth in APAC and Rest of World (together >40% YoY).
Installed Base and Unit Growth
Cytek added 125 units in Q1, bringing installed base to 3,789 units; total instrument unit volume increased 9% year-over-year and FSP instruments increased 3% year-over-year.
Product Adoption: Aurora & Cytek Cloud
Aurora analyzer category revenue rose ~8% year-over-year since launch of the Aurora Evo; Cytek Cloud grew to >26,000 users (about 8 users per installed FSP instrument), supporting ecosystem engagement.
Balance Sheet Strength
Cash, cash equivalents and marketable securities totaled $262.2M as of March 31, 2026 (up slightly from $261.5M at year-end 2025), providing financial flexibility to invest in growth.
Affirmed Full-Year Guidance & Path to Profitability
Company reaffirmed full-year 2026 revenue guidance of $205M–$212M (implying ~2%–5% growth) and expects adjusted EBITDA to improve through the year and be positive for full-year 2026, assuming typical seasonality.
DE:8EQ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:8EQ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €4.12 | €3.94 | -4.37% |
Feb 26, 2026 | €3.68 | €3.64 | -1.11% |
Nov 05, 2025 | €3.36 | €3.62 | +7.74% |
Aug 06, 2025 | €3.30 | €3.22 | -2.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cytek Biosciences, Inc. (DE:8EQ) report earnings?
Cytek Biosciences, Inc. (DE:8EQ) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Cytek Biosciences, Inc. (DE:8EQ) earnings time?
Cytek Biosciences, Inc. (DE:8EQ) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Cytek Biosciences, Inc. stock?
The P/E ratio of Cytek Biosciences is N/A.
What is DE:8EQ EPS forecast?
DE:8EQ EPS forecast for the fiscal quarter 2026 (Q2) is -0.07.